XBiotech Inc. (XBIT) Increases Again; Strong Momentum for Buyers

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 3.35% or $0.21 during the last trading session, reaching $6.47. About 90,063 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 30, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
The move comes after 9 months positive chart setup for the $231.75M company. It was reported on Jan, 30 by Barchart.com. We have $6.73 PT which if reached, will make NASDAQ:XBIT worth $9.27 million more.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” on January 28, 2019, also Seekingalpha.com with their article: “XBiotech’s bermekimab shows positive effect dermatitis pilot study; shares up 28% premarket – Seeking Alpha” published on September 13, 2018, Nasdaq.com published: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” on December 26, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” published on December 12, 2018 as well as Seekingalpha.com‘s news article titled: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” with publication date: January 23, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $231.75 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *